National Jewish Health

Other

Okayama University

National Jewish Medical and Research Center

Kringle Pharma Inc.

Arihiko Kanehiro

Erwin W Gelfand

Michael F Lahn

Willi K Born

Toshikazu Nakamura

Kunio Matsumoto

Hiroki Kakuta

Wataru Ito

Daisuke Morichika

Naohiro Oda

Nobuaki Miyahara

Mitsune Tanimoto

Utako Fujii

Akihiko Taniguchi

A method for treating an inflammatory respiratory disease, comprising administering an effective amount of an RXR agonist represented by formula (1) or (2) as an active ingredient. wherein D, R, R, X, Y, Z, R, R, X, Y, X, Yand Zare defined.

Medicinal composition for preventing or treating inflammatory respiratory disease

Disclosed is a method to reduce airway hyperresponsivesness in an animal by the direct delivery to the lungs of aerosolized antibodies against T cell receptors. The method is particularly useful for treating airway hyperresponsiveness associated with allergic inflammation, is effective at extremely low doses of antibody, and does not have a substantial effect on the peripheral immune system.

Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies

Disclosed is a method for regulation of airway hyperresponsiveness by modulating the action of &#x3b3;&#x3b4; T cells in a patient. Also disclosed are methods for identifying compounds that regulate airway hyperresponsiveness by modulating &#x3b3;&#x3b4; T cell action.

Modulation of gamma delta T cells to regulate airway hyperresponsiveness

A preventive or therapeutic agent for asthma, comprising HGF or its salt as an active ingredient.

Asthma preparation

Disclosed is a method for regulation of airway hyperresponsiveness by modulating the action of &ggr;&dgr; T cells in a patient. Also disclosed are methods for identifying compounds hyperresponsiveness by modulating &ggr;&dgr; T cell action.

Modulation of &ggr;&dgr; T cells to regulate airway hyperresponsiveness

Growing community of inventors

Okayama, Japan

Arihiko Kanehiro